Efficacy and Safety of Entacapone Combined With Madopar in the Treatment of Early Parkinson's Disease: An Observational, Multicenter, Case-Control Study
This observational, multicenter, case-control study aims to evaluate the efficacy and safety of Entacapone combined with Madopar (levodopa/benserazide) in the treatment of early-stage Parkinson's disease (PD) among Chinese patients. The study will enroll patients diagnosed with PD according to the MDS criteria, aged 18-80, with modified Hoehn-Yahr stages 1-2.5, and who have not previously used Entacapone. Participants will be assigned to two groups based on their prior treatment history: the LBE group (levodopa/benserazide/entacapone) or the LB group (levodopa/benserazide only), according to their actual clinical treatment plan.
The study will observe patients over a 24-week period, evaluating changes in motor symptoms using the MDS-UPDRS Part III score as the primary endpoint. Secondary outcomes include assessments of daily living abilities, motor complications, quality of life (PDQ-39), cognitive function (MMSE), global impression (CGI), and safety profiles, including adverse event reporting.
This study does not involve any interventional treatment changes; all therapeutic decisions remain at the discretion of the treating physicians. The findings are expected to provide real-world evidence regarding the potential benefits and safety of adding Entacapone to Madopar in the management of early PD.
Eligibility
Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria:
Age between 18 and 80 years;
Diagnosed with Parkinson's Disease based on the MDS criteria, confirmed by a movement disorder neurologist;
Modified Hoehn and Yahr stage between 1 and 2.5;
No prior use of entacapone;
MMSE score ≥ 26;
BDI (Beck Depression Inventory) score \< 15;
Either:
Has never used levodopa before, or
Has been on a stable dose of levodopa (300-600 mg/day) for at least 1 month prior to enrollment;
Stable doses of amantadine, anticholinergics, dopamine agonists, selegiline, or rasagiline are allowed if maintained for at least 30 days prior to and during the study;
Willing and able to give informed consent and comply with study procedures, with caregiver support if needed.
Exclusion Criteria:
Previous use of entacapone or tolcapone for more than 30 days, or within 4 weeks before baseline;
Use of dopamine agonists within 4 weeks before baseline;
BDI score ≥ 15;
MMSE score \< 26;
Unstable levodopa dosage;
History of dyskinesia;
Diagnosis of atypical or secondary parkinsonism, or history of PD-related neurosurgery;
Clinically significant medical conditions within the past 5 years that could interfere with study participation;
Use of medications known to induce parkinsonism;
Participation in other investigational drug trials within 30 days before baseline.
Primary outcome measure(s)
Change from baseline to Week 24 in the MDS-UPDRS Part III (Motor Examination) score — Baseline to Week 24 The MDS-UPDRS Part III (Motor Examination) assesses the motor function of patients with Parkinson's disease. The total score ranges from 0 to 132, with higher scores indicating greater motor impairment. The change from baseline to Week 24 will be analyzed to evaluate treatment efficacy.
Trial sites (1)
Facility
City
Region
Status
The First Affiliated Hospital of Guangxi Medical University
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.